NAMSW - NewAmsterdam Pharma Company N.V. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

NAMSW

NEWAMSTERDAM PHARMA COMPANY N.V.

NASDAQ

$11.00

▼ DOWN 8.33% (-1.00)

KEY STATISTICS

Market Cap$2.36 B

52w High$30.45

52w Low$11.00

Dividend Yield—

Frequency—

P/E-5.13

Volume1.50K

Shares Out.116.90M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Michael Harvey Davidson Facp.

COMPENSATION 2026

Salary$646,152

Stock Awards$3,571,146

Incentive Plan Pay$474,922

All Other Comp.$18,068

Total$13,641,854

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 10, 2021

METHOD OF GOING PUBLIC

N/A

FULL TIME EMPLOYEES

100

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.$7.54M

NOV

WED

PRICE

$11.00 ▼ DOWN 8.33% (−$1.00)

About NewAmsterdam Pharma Company N.V.

https://www.newamsterdampharma.com ↗

NewAmsterdam Pharma N.V., founded in 2019 in the Netherlands, is a clinical-stage biopharmaceutical company developing obicetrapib, a CETP inhibitor aimed at improving lipid profiles and patient care in metabolic diseases.

INDUSTRY

Biotechnology

A PRODUCT NEWAMSTERDAM PHARMA COMPANY N.V. IS KNOWN FOR

Obicetrapib

Obicetrapib, developed by NewAmsterdam Pharma, is an investigational oral CETP inhibitor in late-stage Phase 3 trials aimed at lowering LDL cholesterol and reducing cardiovascular risk, with regulatory decisions expected in Europe in late 2026.